High-Dose Plasmid-Mediated VEGF Gene Transfer is Safe in Patients With Severe Ischemic Heart Disease (GENESIS-I). A Phase I, Open-Label, Two-Year Follow-up Trial

ObjectivesWe aimed to assess safety and, secondarily, the efficacy of intramyocardial high-dose plasmid-vascular endothelial growth factor (VEGF) 165 (pVEGF165) gene transfer in no-option patients with coronary artery disease (CAD). BackgroundControlled trials of pVEGF165 in CAD have shown little benefit. One possible reason is shortness of dosage. We have shown in large mammalian models of chronic myocardial ischemia and acute myocardial infarction that intramyocardial pVEGF165 at doses significantly higher than those used in recent phase II trials is safe and efficacious on myocardial perfusion, left ventricular function, and infarct size limitation. MethodsUsing an injection catheter, 10 patients with severe CAD not amenable for revascularization received 10 intramyocardial injections of 0.38 mg (total dose, 3.8 mg) pVEGF165 in zones exhibiting myocardial ischemia, as assessed by combined stress 99mTc-sestamibi single-photon emission computed tomography and stress echocardiography. ResultsNo serious adverse events related to either VEGF or the injection procedure occurred over the 2-year follow-up. One patient suffered femoral artery thrombosis after a follow-up coronary angiography, successfully resolved with medical treatment. Six patients suffered uncomplicated coronary ischemic events during the second year follow-up. Angina functional class decreased from 2.6 0.2 to 1.2 +/- 0.3 (mean +/- SEM, P < 0.05), quality of life increased from 56.9 +/- 3.2 to 82.6 +/- 2.4 (P < 0.05), the summed difference score of myocardial perfusion decreased from 13.4 +/- 2 to 7.7 +/- 1.8 (P < 0.04), and stress ejection fraction did not change (44.2 +/- 3.6% to 47.8 +/- 3.1%, P = NS). ConclusionsHigh-dose intramyocardial pVEGF165 is safe at 2 years follow-up in patients with severe CAD. The efficacy results observed must be taken cautiously given the uncontrolled, open-label study design. (c) 2012 Wiley Periodicals, Inc.